Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 14, Number 3—March 2008
Research

Mycobacterium xenopi Clinical Relevance and Determinants, the Netherlands

Jakko van Ingen*†Comments to Author , Martin J. Boeree*, Wiel C.M. de Lange*, Wouter Hoefsloot*, Saar A. Bendien*, Cecile Magis-Escurra*, Richard Dekhuijzen*, and Dick van Soolingen†
Author affiliations: *Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands; †National Institute for Public Health and the Environment, Bilthoven, the Netherlands;

Main Article

Table 1

Baseline population characteristics of 49 patients with nontuberculous mycobacterial infection, the Netherlands, January 1999 through March 2005*

Characteristic ATS+ (n = 25) ATS– (n = 24) Total (%)
Demographics
Male sex 19 18 37 (76)
Mean age, y 60 60 60
Dutch origin
24
20
44 (90)
Concurrent and predisposing conditions
Pre-existing pulmonary disease 21 18 39 (80)
Chronic obstructive pulmonary disease 17 14 31 (63)
Lung cancer 1 3 4 (8)
Prior tuberculosis 0 2 2 (4)
Recurrent pulmonary infection† 5 2 7 (14)
Bronchiectasis 2 4 6 (12)
Smoker, current/ past 15/ 6 11/ 3 35 (71)
Alcohol abuse 2 3 5 (10)
High-dose steroid use‡ 3 5 8 (16)
HIV infection 2 5 7 (14)
Mean CD4 count in HIV-infected patients, cells/mL 226 126 159
Hematologic malignancy 0 1 1 (2)
Otherwise impaired immunity§
2
1
3 (6)
Signs and symptoms
Productive cough 21 20 41 (84)
Hemoptysis 5 4 9 (18)
Dyspnea 14 9 23 (47)
Fever 11 6 17 (35)
Weight loss 12 7 19 (39)
Malaise
16
10
26 (53)
Chest radiographic abnormalities
Infiltrate 15 12 27 (55)
Cavity 12¶ 3 15 (31)
Pleural thickening 3 4 7 (14)
Emphysema 9 9 18 (37)
Space-occupying lesion 1 3 4 (8)

*ATS+, American Thoracic Society diagnostic criteria for nontuberculous mycobacterialinfection met; ATS–, ATS diagnostic criteria for nontuberculous mycobacterial infection not met.
†>3 requiring treatment in 6 months before primary Mycobacteria xenopi culture.
>15 mg prednisone/day for >3 months before primary M. xenopi culture.
§Diabetes mellitus, cisplatinum chemotherapy, anorexia nervosa (all n = 1).
¶Significant association (odds ratio 14.3, 95% confidence interval 2.7–75.6, p = 0.001).

Main Article

Page created: July 07, 2010
Page updated: July 07, 2010
Page reviewed: July 07, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external